Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
State of the Art of Pharmaceutical Research in Brazil
share announcement

State of the Art of Pharmaceutical Research in Brazil

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 6046

Special Issue Editors

Dr. Nubia Boechat

E-Mail Website
Guest Editor
Departamento de Síntese de Farmacos, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil
Interests: medicinal chemistry, neglected diseases, malaria, chagas diseases, tuberculosis
Dr. Frederico Silva Castelo Branco

E-Mail Website
Guest Editor
Laboratorio de Sintese de Farmacos - LASFAR, Fundacao Oswaldo Cruz, Instituto de Tecnologia em Farmacos, Farmanguinhos -Manguinhos, Rio de Janeiro CEP 21041-250, Brazil
Interests: medicinal chemistry; neglected diseases; chagas diseases; tuberculosis

Special Issue Information

Dear Colleagues,

Brazil is the seventh largest pharmaceutical market in terms of revenue in the ranking of the 20 main economies in the world. Accounting for approximately 3-4% of this global market, this country is the main player in Latin America.

Although the main Big Pharma companies are present in Brazil, in this country, pharmaceutical research is mainly developed in universities and research public institutes. Parallelly, few Brazilian pharmaceutical companies have P&D initiatives.

Instead, incremental innovations, such as the development of new formulations or fixed-dose combinations, are made in Brazilian pharmaceuticals due to the high cost of radical innovations regarding new Active Pharmaceutical Ingredients (APIs). Research into radical innovations is carried out in universities and research institutes, which is mainly funded by the government and rarely reaches the market. The main objective of these research projects is usually to investigate new drugs for the treatment of tropical diseases in order to meet internal public health demands. In these cases, competition with research centers with great physical and financial structures is more favorable. Another important point that favors the search for new drugs for the treatment of these tropical diseases is the intrinsic knowledge acquired over decades by researchers about diseases, vectors and etiological agents that specifically affect the populations of different regions of the country.

On the other hand, many researchers have established solid scientific collaboration with institutions abroad focusing on diseases such as cancer, Alzheimer's and other illnesses that present high costs to the country's health system.

In Brazil, there are also some established companies that work by outsourcing services for some of the stages in the development of an API. These can range from discovery, pre-clinical development, API scaling, formulation development, clinical development, registration, and manufacturing.

In this Special Issue, we cover a variety of the main approaches in pharmaceutical research in Brazil. 

Dr. Nubia Boechat
Dr. Frederico Silva Castelo Branco
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

22 pages, 1941 KiB  
Article
Antiplasmodial, Trypanocidal, and Genotoxicity In Vitro Assessment of New Hybrid α,α-Difluorophenylacetamide-statin Derivatives
by Carlos Fernando Araujo-Lima, Rita de Cassia Castro Carvalho, Sandra Loureiro Rosario, Debora Inacio Leite, Anna Caroline Campos Aguiar, Lizandra Vitoria de Souza Santos, Julianna Siciliano de Araujo, Kelly Salomão, Carlos Roland Kaiser, Antoniana Ursine Krettli, Monica Macedo Bastos, Claudia Alessandra Fortes Aiub, Maria de Nazaré Correia Soeiro, Nubia Boechat and Israel Felzenszwalb
Pharmaceuticals 2023, 16(6), 782; https://doi.org/10.3390/ph16060782 - 24 May 2023
Cited by 1 | Viewed by 1271
Abstract
Background: Statins present a plethora of pleiotropic effects including anti-inflammatory and antimicrobial responses. A,α-difluorophenylacetamides, analogs of diclofenac, are potent pre-clinical anti-inflammatory non-steroidal drugs. Molecular hybridization based on the combination of pharmacophoric moieties has emerged as a strategy for the development of new candidates [...] Read more.
Background: Statins present a plethora of pleiotropic effects including anti-inflammatory and antimicrobial responses. A,α-difluorophenylacetamides, analogs of diclofenac, are potent pre-clinical anti-inflammatory non-steroidal drugs. Molecular hybridization based on the combination of pharmacophoric moieties has emerged as a strategy for the development of new candidates aiming to obtain multitarget ligands. Methods: Considering the anti-inflammatory activity of phenylacetamides and the potential microbicidal action of statins against obligate intracellular parasites, the objective of this work was to synthesize eight new hybrid compounds of α,α-difluorophenylacetamides with the moiety of statins and assess their phenotypic activity against in vitro models of Plasmodium falciparum and Trypanosoma cruzi infection besides exploring their genotoxicity safety profile. Results: None of the sodium salt compounds presented antiparasitic activity and two acetated compounds displayed mild anti-P. falciparum effect. Against T. cruzi, the acetate halogenated hybrids showed moderate effect against both parasite forms relevant for human infection. Despite the considerable trypanosomicidal activity, the brominated compound revealed a genotoxic profile impairing future in vivo testing. Conclusions: However, the chlorinated derivative was the most promising compound with chemical and biological profitable characteristics, without presenting genotoxicity in vitro, being eligible for further in vivo experiments. Full article
(This article belongs to the Special Issue State of the Art of Pharmaceutical Research in Brazil)
►▼ Show Figures

Figure 1

14 pages, 2392 KiB  
Article
Nanoencapsulation of Vaccinium ashei Leaf Extract in Eudragit® RS100-Based Nanoparticles Increases Its In Vitro Antioxidant and In Vivo Antidepressant-like Actions
by Verciane Schneider Cezarotto, Eduarda Piovesan Franceschi, Ana Cristina Stein, Tatiana Emanuelli, Luana Haselein Maurer, Marcel Henrique Marcondes Sari, Luana Mota Ferreira and Letícia Cruz
Pharmaceuticals 2023, 16(1), 84; https://doi.org/10.3390/ph16010084 - 07 Jan 2023
Cited by 2 | Viewed by 1489
Abstract
Depression is a major psychiatric disorder in Brazil and worldwide. Vaccinium ashei (V. ashei) leaves are cultivation by-products with high bioactive compound levels. Here, a hydroalcoholic extract of V. ashei leaves (HEV) was associated with Eudragit® RS100-based nanoparticles (NPHEV) to evaluate [...] Read more.
Depression is a major psychiatric disorder in Brazil and worldwide. Vaccinium ashei (V. ashei) leaves are cultivation by-products with high bioactive compound levels. Here, a hydroalcoholic extract of V. ashei leaves (HEV) was associated with Eudragit® RS100-based nanoparticles (NPHEV) to evaluate the in vitro antioxidant and in vivo antidepressant-like effects. Interfacial deposition of the preformed polymer method was used for NPHEV production. The formulations were evaluated regarding physicochemical characteristics, antioxidant activity (DPPH radical scavenging and oxygen radical absorbance capacity), and antidepressant-like action (1–25 mg/kg, single intragastric administration) assessed in forced swimming and tail suspension tests in male Balb-C mice. The NPHEV presented sizes in the nanometric range (144–206 nm), positive zeta potential values (8–15 mV), polydispersity index below 0.2, and pH in the acid range. The phenolic compound content was near the theoretical values, although the rutin presented higher encapsulation efficiency (~95%) than the chlorogenic acid (~60%). The nanoencapsulation improved the HEV antioxidant effect and antidepressant-like action by reducing the immobility time in both behavioral tests. Hence, Eudragit® RS100 nanoparticles containing HEV were successfully obtained and are a promising alternative to manage depression. Full article
(This article belongs to the Special Issue State of the Art of Pharmaceutical Research in Brazil)
►▼ Show Figures

Figure 1

Other

Jump to: Research

12 pages, 298 KiB  
Perspective
Cardiovascular Safety and Benefits of Testosterone Implant Therapy in Postmenopausal Women: Where Are We?
by Guilherme Renke and Francisco Tostes
Pharmaceuticals 2023, 16(4), 619; https://doi.org/10.3390/ph16040619 - 20 Apr 2023
Cited by 3 | Viewed by 2922
Abstract
We discuss the CV safety and efficacy data for subcutaneous testosterone therapy (STT) in postmenopausal women. We also highlight new directions and applications of correct dosages performed in a specialized center. To recommend STT, we propose innovative criteria (IDEALSTT) according to total testosterone [...] Read more.
We discuss the CV safety and efficacy data for subcutaneous testosterone therapy (STT) in postmenopausal women. We also highlight new directions and applications of correct dosages performed in a specialized center. To recommend STT, we propose innovative criteria (IDEALSTT) according to total testosterone (T) level, carotid artery intima-media thickness, and calculated SCORE for a 10-year risk of fatal cardiovascular disease (CVD). Despite all the controversies, hormone replacement therapy (HRT) with T has gained prominence in treating pre and postmenopausal women in the last decades. HRT with silastic and bioabsorbable testosterone hormone implants has gained prominence recently due to its practicality and effectiveness in treating menopausal symptoms and hypoactive sexual desire disorder. A recent publication on the complications of STT, looking at a large cohort of patients over seven years, demonstrated its long-term safety. However, the cardiovascular (CV) risk and safety of STT in women are still controversial. Full article
(This article belongs to the Special Issue State of the Art of Pharmaceutical Research in Brazil)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop